BillionToOne closed at $113.89 on Nov 4, up 3.11%, 24.1% below its 52-week closing high. Volume of 582.8K shares was 1.24× its 20-day average (close to normal).
Split-adjusted performance: +14.0% over one month, +39.9% over six months.
In the quarter ended Jun 30, 2026, revenue was $109.45M, with a net margin of 7.4%.
Short interest was 2.9M shares at the Oct 15 settlement, up 4.0% from the prior report (12.0% of float, 5.5 days to cover).
No reported quarters with price history yet.
Percentile among 24 companies (100 = best)
Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BLLNBillionToOne | $113.89 | +3.11% | +39.9% | — | 7.4% | — | $5.37B | |
| RDNTRadNet | $80.26 | +9.67% | +36.9% | +25.0% | 1.2% | — | $6.32B | Compare |
| CDNACareDx | $85.86 | −2.95% | +309.8% | +39.3% | 13.8% | 35.1 | $4.51B | Compare |
| GRALGRAIL | $143.66 | +3.03% | +128.9% | +25.7% | −246.7% | — | $6.42B | Compare |
| VCYTVeracyte | $52.52 | +4.43% | +27.5% | +15.5% | 17.0% | 36.9 | $4.22B | Compare |
| CELCCelcuity | $69.24 | −0.69% | −50.3% | — | — | — | $3.39B | Compare |
| CAICaris Life Sciences | $33.22 | +1.13% | +73.7% | +45.4% | −0.2% | 89.3 | $9.39B | Compare |
| FTREFortrea Holdings | $20.83 | −0.57% | +33.2% | −1.4% | 0.1% | — | $2.01B | Compare |
| PSNLPersonalis | $15.79 | +0.25% | +160.1% | +30.0% | −141.7% | — | $1.69B | Compare |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
